The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease

被引:22
|
作者
Peng, Fang [1 ]
Lu, Linyu [2 ]
Wei, Fei [2 ]
Wu, Die [2 ]
Wang, Kai [2 ]
Tang, Juanjuan [2 ]
机构
[1] Yangzhou Univ, Guangling Coll, Yangzhou, Jiangsu, Peoples R China
[2] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med, Dept Physiol, Nanjing 210023, Peoples R China
基金
中国国家自然科学基金;
关键词
neuroinflammation; onjisaponin B; oxidative stress; Parkinson's disease; RhoA-ROCK2; RHO-KINASE; DEGENERATION; INHIBITION; NEURONS; INVOLVEMENT; EXPRESSION; PROTECTS; RECEPTOR; PATHWAY;
D O I
10.1097/WNR.0000000000001428
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Onjisaponin B (OB) is the main active ingredient of the traditional Chinese medicinal herb polygala, which is effective against neurodegenerative disorders. However, the target of OB is currently unknown. Neuroinflammation and oxidative stress are both risk factors for the pathogenesis and progression of Parkinson's disease (PD). Here, we used a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced subacute mouse model of PD to explore the efficacy and neuroprotective mechanism of OB in PD. Immunohistochemistry was used to mark dopaminergic (DA) neurons and microglia in the substantia nigra pars compact. Administration of OB (20 and 40 mg/kg) prevented the degeneration of DA neurons and improved motor impairment in the rotarod test. Furthermore, OB attenuated microglia over-activation and reduced the secretion of inflammatory factors including tumor necrosis factor-alpha, interleukin-1 beta (IL-1 beta) and interleukin-6 (IL-6), as determined by ELISA. Meanwhile, the activities of superoxide dismutase and malondialdehyde were used to measure the level of oxidative stress in brain homogenates and suppression of excessive lipid epoxidation and increased antioxidant enzyme activity were found in OB-treated PD mice. Finally, OB inhibits the expression of the p65 subunit of NF-kappa B in the nucleus and attenuated expression of the RhoA and ROCK2 proteins in PD mice. Consequently, our results show that OB ameliorates DA neurodegeneration in a MPTP-induced mouse model of PD through anti-oxidant and anti-inflammatory activities mediated via the RhoA/ROCK2 signaling pathway. This finding demonstrates that OB may be a promising drug for DA neuron degeneration, which may provide a new therapeutic agent for future discovery of drugs for PD.
引用
收藏
页码:456 / 465
页数:10
相关论文
共 50 条
  • [31] Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson's Disease
    Schintu, Nicoletta
    Frau, Lucia
    Ibba, Marcello
    Garau, Arianna
    Carboni, Ezio
    Carta, Anna R.
    NEUROTOXICITY RESEARCH, 2009, 16 (02) : 127 - 139
  • [32] Progressive Dopaminergic Degeneration in the Chronic MPTPp Mouse Model of Parkinson’s Disease
    Nicoletta Schintu
    Lucia Frau
    Marcello Ibba
    Arianna Garau
    Ezio Carboni
    Anna R. Carta
    Neurotoxicity Research, 2009, 16 : 127 - 139
  • [33] Protective Effects of Onjisaponin B in a Mouse Model of Alzheimer's Disease via Enhancement of Hippocampal Neuroplasticity
    Zhang, Ling
    Zha, Xiaoyu
    Li, Gaowen
    Chen, Qun
    Xia, Qing
    CURRENT TOPICS IN NUTRACEUTICAL RESEARCH, 2022, 20 (03) : 498 - 504
  • [34] Bacopaside-I ameliorates motor dysfunction and neurodegeneration in rat model of Parkinson's disease
    Singh, Babita
    Pandey, Shivani
    Rumman, Mohammad
    Gupta, Mrinal
    Mahdi, Abbas Ali
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, : 6113 - 6122
  • [35] Brain-specific NRSF deficiency aggravates dopaminergic neurodegeneration ana impairs neurogenesis in the MPTP mouse model of Parkinson's disease
    Huang, Dongping
    Li, Qing
    Wang, Yi
    Liu, Zhaolin
    Wang, Zishan
    Li, Heng
    Wang, Jinghui
    Su, Jing
    Ma, Yuanyuan
    Yu, Mei
    Fei, Jian
    Huang, Fang
    AGING-US, 2019, 11 (10): : 3280 - 3297
  • [36] Systemic lipopolysaccharide-induced inflammatory reaction exacerbates dopaminergic neurodegeneration in a MPTP-induced mouse model of Parkinson's disease
    Seike, S.
    Arai, H.
    Mochizuki, H.
    Mizuno, Y.
    MOVEMENT DISORDERS, 2006, 21 : S579 - S580
  • [37] Mitoapocynin Treatment Protects Against Neuroinflammation and Dopaminergic Neurodegeneration in a Preclinical Animal Model of Parkinson's Disease
    Ghosh, Anamitra
    Langley, Monica R.
    Harischandra, Dilshan S.
    Neal, Matthew L.
    Jin, Huajun
    Anantharam, Vellareddy
    Joseph, Joy
    Brenza, Timothy
    Narasimhan, Balaji
    Kanthasamy, Arthi
    Kalyanaraman, Balaraman
    Kanthasamy, Anumantha G.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2016, 11 (02) : 259 - 278
  • [38] Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease
    Ishibashi, K.
    Kanemaru, K.
    Saito, Y.
    Murayama, S.
    Oda, K.
    Ishiwata, K.
    Mizusawa, H.
    Ishii, K.
    ACTA NEUROLOGICA SCANDINAVICA, 2010, 122 (01): : 46 - 51
  • [39] Quantitative PET analysis of subregional striatal dopaminergic neurodegeneration in the MPTP primate model of Parkinson's disease
    Park, S. H.
    Park, H. S.
    Kim, B. S.
    Lim, S. M.
    Yang, S.
    Chang, K. -T.
    Lee, S. -R.
    Lee, Y.
    Kim, S. E.
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2017, 37 : 235 - 236
  • [40] SINEUP for GDNF rescues motor deficits and neurodegeneration in a mouse model of Parkinson's disease
    Espinoza, S.
    Scarpato, M.
    Damiani, D.
    Manago, F.
    Mereu, M.
    Contestabile, A.
    Papaleo, F.
    Mingozzi, F.
    Ronzitti, G.
    Zucchelli, S.
    Gustincich, S.
    HUMAN GENE THERAPY, 2018, 29 (12) : A86 - A86